← Leaderboards
Christopher D Link
University Of Colorado At Boulder
$10,776,150
Attributed
$15,097,119
Total exposure
7
Grants
5
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $4.1M · FY2005–25$5M$3.8M$2.5M$1.3M$0
'05
'06
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$15,097,119 · 7
By mechanism
R01$9,734,813 · 4
RF1$4,384,378 · 1
R21$977,928 · 2
Top collaborators
- Charles A Hoeffer5 shared
- James R Cypser3 shared
- Thomas E. Johnson3 shared
- Mark R Opp3 shared
- Yongjie Zhang2 shared
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposCaenorhabditis ElegansPathologyNeuronsMolecularProteinsGenesS DiseaseComplementBaseIn VivoResponseCellsPathway InteractionsNeurodegenerative DisordersMutationToxic EffectTransgenic OrganismsTranscriptDepositionCell Culture TechniquesStructureEngineeringIn Vitro
Grant awards (37)
Double-stranded RNA in neuronal cell death in Alzheimer's and related neurodegenerative diseases$760,995
R01 · FY2025 · AG · contact PI
Double-stranded RNA in neuronal cell death in Alzheimer's and related neurodegenerative diseases$768,931
R01 · FY2024 · AG · contact PI
Sleep Disruption and Alzheimer's Disease Pathology$390,259
RF1 · FY2022 · AG
C. Elegans as a Model of Cell Senescence and Alzheimer's Disease$192,500
R21 · FY2021 · AG
C. Elegans as a Model of Cell Senescence and Alzheimer's Disease$143,650
R21 · FY2021 · AG
C. Elegans as a Model of Cell Senescence and Alzheimer's Disease$231,000
R21 · FY2020 · AG
Sleep Disruption and Alzheimer's Disease Pathology$191,303
RF1 · FY2020 · AG
Sleep Disruption and Alzheimer's Disease Pathology$3,802,816
RF1 · FY2019 · AG
TDP-43, RNA Metabolism, and ALS/FTD Pathology$338,516
R01 · FY2019 · NS · contact PI
TDP-43, RNA Metabolism, and ALS/FTD Pathology$338,516
R01 · FY2018 · NS · contact PI
TDP-43, RNA Metabolism, and ALS/FTD Pathology$417,196
R01 · FY2017 · NS · contact PI
TDP-43, RNA Metabolism, and ALS/FTD Pathology$338,516
R01 · FY2016 · NS · contact PI
Abeta Oligomers and Mechanisms of Neuronal Cell Death in Alzheimer's Disease$186,271
R21 · FY2016 · AG · contact PI
TDP-43, RNA Metabolism, and ALS/FTD Pathology$78,680
R01 · FY2016 · NS · contact PI
TDP-43, RNA Metabolism, and ALS/FTD Pathology$349,453
R01 · FY2015 · NS · contact PI
Abeta Oligomers and Mechanisms of Neuronal Cell Death in Alzheimer's Disease$224,507
R21 · FY2015 · AG · contact PI
Investigation of TDP-43 Function and Toxicity in C. elegans$314,342
R01 · FY2013 · NS · contact PI
Investigation of TDP-43 Function and Toxicity in C. elegans$325,742
R01 · FY2012 · NS · contact PI
Transgenic C. elegans as Amyloid Disease Model$297,134
R01 · FY2012 · AG · contact PI
Investigation of TDP-43 Function and Toxicity in C. elegans$325,742
R01 · FY2011 · NS · contact PI
Transgenic C. elegans as Amyloid Disease Model$297,087
R01 · FY2011 · AG · contact PI
Investigation of TDP-43 Function and Toxicity in C. elegans$329,067
R01 · FY2010 · NS · contact PI
Transgenic C. elegans as Amyloid Disease Model$309,033
R01 · FY2010 · AG · contact PI
Investigation of TDP-43 Function and Toxicity in C. elegans$343,656
R01 · FY2009 · NS · contact PI
Transgenic C. elegans as Amyloid Disease Model$317,179
R01 · FY2009 · AG · contact PI
Transgenic C. elegans as Amyloid Disease Model$319,868
R01 · FY2008 · AG · contact PI
Transgenic C.elegans as Amyloid Disease Model$343,032
R01 · FY2006 · AG · contact PI
Comparative Modeling of Neurodegenerative Diseases$282,267
R01 · FY2006 · AG · contact PI
Transgenic C.elegans as Amyloid Disease Model$340,769
R01 · FY2005 · AG
Comparative Modeling of Neurodegenerative Diseases$288,979
R01 · FY2005 · AG
Transgenic C.elegans as Amyloid Disease Model$329,735
R01 · FY2004 · AG
Comparative Modeling of Neurodegenerative Diseases$288,009
R01 · FY2004 · AG
Transgenic C.elegans as Amyloid Disease Model$366,706
R01 · FY2003 · AG
Comparative Modeling of Neurodegenerative Diseases$284,326
R01 · FY2003 · AG
TRANSGENIC C. ELEGANS AS AMYLOID DISEASE MODEL$289,095
R01 · FY2001 · AG
TRANSGENIC C. ELEGANS AS AMYLOID DISEASE MODEL$71,503
R01 · FY2001 · AG
TRANSGENIC C. ELEGANS AS AMYLOID DISEASE MODEL$280,739
R01 · FY2000 · AG